Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14287 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Christin Rogers Marks und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Graft Survival, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, National Institute of Aging.
Abstract (Originalsprache)
Purpose
Kidney transplantation has a survival benefit for people with human immunodeficiency virus (HIV) and end‐stage kidney disease, however increased rates of rejection remain an issue. Questions remain regarding the impact of induction immunosuppression therapy and antiretroviral (ARV) choice on long‐term outcomes.
Methods
We performed a multicenter retrospective analysis of outcomes in recipients with HIV who received kidneys from donors without HIV transplanted between 2004 and 2019. The association between induction and ARV regimens and long‐term outcomes including rejection, graft, and recipient survival over 5 years was investigated using Cox regression modeling.
Results
Seventy‐eight kidney transplants (KT) performed in 77 recipients at five US transplant centers were included, with median follow up of 7.1 (4.3–10.7) years. Overall recipient and graft survival were 83% and 67%, respectively. Rejection occurred in 37% (29/78). Recipients with rejection were more likely to be younger, recipients of deceased donor organs, and Black. Receipt of rabbit anti‐thymocyte globulin (rATG) induction without protease‐inhibitor (PI)‐based ARVs was associated with 83% lower risk of rejection (adjusted hazard ratio (aHR) 0.17 (95% CI 0.05–0.63), p =.007) and a non‐statistically significantly lower risk of graft failure (aHR 0.18 (0.03–1.16), p =.07) when compared to those who received other induction and ARV combinations.
Conclusions
In this multicenter retrospective study, we found a trend toward lower rejection and improved graft survival among those who received both rATG for induction and PI‐sparing ARVs. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Johns Hopkins Medical Center, Baltimore, Maryland, USA.
- Ochsner Health, New Orleans, Louisiana, USA.
- Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana, USA.
- Division of Infectious Disease, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA.
- Yale New Haven Hospital, New Haven, Connecticut, USA.
ORCID-Profile: Christin Rogers Marks, Maricar Malinis, Carolyn D Alonso
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- National Institute of Aging
Zitieren
APA
Marks, C. R., Durand, C. M., Bowring, M. G., Hand, J., Abidi, M. Z., Malinis, M., Barnaba, B., Patel, H., Pavlakis, M., & Alonso, C. D. (2024). Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency. Transplant Infectious Disease. https://doi.org/10.1111/tid.14287
Vancouver
Marks CR, Durand CM, Bowring MG, Hand J, Abidi MZ, Malinis M, et al. Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency. Transplant Infectious Disease. 2024. doi:10.1111/tid.14287
BibTeX
@article{Marks2024,
author = {Marks, Christin Rogers and Durand, Christine M and Bowring, Mary G and Hand, Jonathan and Abidi, Maheen Z and Malinis, Maricar and Barnaba, Brittany and Patel, Het and Pavlakis, Martha and Alonso, Carolyn D},
title = {Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14287}
}
EUVIMED